Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer – A Feasibility Study

Title: Whole Exome Analysis to Select Targeted Therapies for Patients with Metastatic Breast Cancer – A Feasibility Study
Authors: Jaeger, Bernadette Anna Sophia; Krawczyk, Natalia; Japp, Anna Sophia; Honisch, Ellen; Köhrer, Karl; Scheuring, Sibylle; Petzsch, Patrick; Neubauer, Hans; Volkmer, Anne Kathrin; Esposito, Irene; Ruckhäberle, Eugen; Niederacher, Dieter; Fehm, Tanja
Contributors: Förderung Krebsforschung Nordrhein-Westfalen e.V
Source: Geburtshilfe und Frauenheilkunde ; volume 83, issue 09, page 1138-1147 ; ISSN 0016-5751 1438-8804
Publisher Information: Georg Thieme Verlag KG
Publication Year: 2023
Description: The purpose of this feasibility study was to select targeted therapies according to “ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)”. Data interpretation was further supported by a browser-based Treatment Decision Support platform (MH Guide, Molecular Health, Heidelberg, Germany). We applied next generation sequencing based whole exome sequencing of tumor tissue and peripheral blood of patients with metastatic breast cancer (n = 44) to detect somatic as well as germline mutations. In 32 metastatic breast cancer patients, data interpretation was feasible. We identified 25 genomic alterations with ESCAT Level of Evidence I or II in 18/32 metastatic breast cancer patients, which were available for evaluation: three copy number gains in HER2, two gBRCA1, two gBRCA2, six PIK3CA, one ESR1, three PTEN, one AKT1 and two HER2 mutations. In addition, five samples displayed Microsatellite instability high-H. Resulting treatment options were discussed in a tumor board and could be recommended in a small but relevant proportion of patients with metastatic breast cancer (7/18). Thus, this study is a valuable preliminary work for the establishment of a molecular tumor board within the German initiative “Center for Personalized Medicine” which aims to shorten time for analyses and optimize selection of targeted therapies.
Document Type: article in journal/newspaper
Language: German
DOI: 10.1055/a-2150-9440
DOI: 10.1055/a-2150-9440.pdf
Availability: https://doi.org/10.1055/a-2150-9440; http://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-2150-9440.pdf
Rights: https://creativecommons.org/licenses/by-nc-nd/4.0/
Accession Number: edsbas.E819FCB2
Database: BASE